AUTHORS
Yan-Ruide Li, PhD, Yuning Chen2, Yichen Zhu3, Xinyuan Shen4
AFFILIATIONS
1 University of California, Los Angeles, Los Angeles, California, United States
2 University of California, Los Angeles, Los Angeles, California, United States
3 University of California, Los Angeles, Los Angeles, California, United States
4 University of California, Los Angeles, Los Angeles, California, United States
ABSTRACT
Background: Chimeric antigen receptor (CAR)-T cell therapies have demonstrated remarkable efficacy in B cell-mediated autoimmune diseases but are associated with significant limitations, including cytokine release syndrome (CRS), neurotoxicity, autologous manufacturing, and limited scalability. Invariant natural killer T (NKT) cells possess intrinsic immunoregulatory functions, exhibit minimal risk of graft-versus-host disease, and can be developed as allogeneic off-the-shelf cellular products. We hypothesized that hematopoietic stem and progenitor cell (HSPC) engineering could enable scalable generation of universal CAR-NKT cells with superior safety and therapeutic efficacy for autoimmune diseases, including multiple sclerosis.
Methods: Human HSPCs were genetically engineered to express a CD19-targeting CAR construct and differentiated into CAR-NKT cells using an optimized clinically-guided feeder-free differentiation platform. Cellular phenotype, purity, and expansion were evaluated by flow cytometry. Therapeutic efficacy was assessed in human CD19+ B-cell malignancy xenograft mouse models. Cytotoxicity against autoreactive immune cells, cytokine production, and safety were evaluated using in vitro functional assays and humanized NSG-SGM3 mice.
Results: CAR-NKT cells generated from engineered HSPCs exhibited robust expansion, high purity, and a mature invariant NKT-cell phenotype suitable for clinical-scale manufacturing. In a experimental autoimmune encephalomyelitis (EAE) model, murine CD19-targeting CAR-NKT cells significantly outperformed conventional CAR-T cells in suppressing disease progression and reducing neurological symptoms. Human allogeneic CD19-targeting CAR-NKT cells efficiently eliminated CD19+ autoreactive B cells and proinflammatory CD1d+ myeloid cells while preserving favorable immune homeostasis. Importantly, HSPC-derived CAR-NKT cells maintained potent cytotoxic activity in RAJI human CD19+ B-cell malignancy xenograft mouse models. In humanized NSG-SGM3 mice, CAR-NKT therapy induced substantially lower CRS-associated cytokine release compared with conventional CAR-T cells, supporting an improved safety profile. These findings demonstrate that HSPC engineering enables the production of universal CAR-NKT cells with potent immunoregulatory function, scalable manufacturing potential, and reduced treatment-related toxicity.
Conclusions: We developed a clinically translatable HSPC engineering platform capable of generating universal, off-the-shelf CAR-NKT cells for autoimmune diseases. HSPC-derived CAR-NKT cells demonstrated superior therapeutic efficacy compared with CAR-T cells in preclinical autoimmune models while maintaining a markedly improved safety profile. This work establishes engineered CAR-NKT cells as a promising next-generation adoptive cellular therapy for autoimmune diseases and supports their further clinical development.
DISCLOSURES
Yan-Ruide Li, PhD: No relevant conflicts of interest to declare.